Microwave Ablation Versus Radiofrequency Ablation for Hepatocellular Carcinoma: A Systematic Review and Meta-Analysis Alexander Muacevic, John R Adler, Lucas Ortiz, Kevin Vasquez, Juan M Lozano, Andres Gonzalez Abstract Microwave ablation (MWA) and radiofrequency ablation (RFA) are established curative-intent treatments for early-stage hepatocellular carcinoma (HCC), but their relative benefits remain uncertain. We systematically synthesized comparative evidence on the effectiveness and safety of MWA versus RFA in adults with HCC. PubMed/Medical Literature Analysis and Retrieval System Online (MEDLINE), Web of Science, Scopus, SciELO, and Latin American and Caribbean Health Sciences Literature (LILACS) were searched through March 2026. Study eligibility, extraction of treatment-specific data, and methodological quality assessment were independently evaluated by two reviewers. Quantitative synthesis used random-effects models, with risk ratios (RRs) for dichotomous endpoints and hazard ratios (HRs) for time-to-event endpoints. Confidence in the evidence for each outcome was judged according to the Grading of Recommendations Assessment, Development and Evaluation (GRADE) framework. Thirty-eight studies, including seven randomized controlled trials, contributed 8,347 participants. Initial complete ablation was similar with MWA and RFA (28 studies; 6,036 participants; RR 1.01, 95% confidence interval (CI) 1.00-1.02; I2=0%). MWA was associated with less local tumor progression (27 studies; 5,166 participants; RR 0.67, 95% CI 0.54-0.83; I2=54%), with a consistent association in randomized trials (RR 0.55, 95% CI 0.40-0.76; I2=0%). No conclusive between-technique differences were found for intrahepatic distant recurrence, overall survival, recurrence-free survival, major or minor complications, or periprocedural mortality. No statistically conclusive difference in initial complete ablation was demonstrated between MWA and RFA. MWA may provide better local control, although current evidence does not show a corresponding survival benefit. Treatment choice should incorporate tumor location, the expected ablation margin, procedural safety, operator experience, technology availability, and cost. Introduction and background Primary liver cancer remains a major cause of cancer mortality, and hepatocellular carcinoma (HCC) represents its predominant histologic type [,]. Within the Barcelona Clinic Liver Cancer (BCLC) 2026 framework, ablative therapy is among the potentially curative treatments considered for very early- and early-stage HCC (BCLC 0/A) patients, together with resection and transplantation, selected according to tumor burden, liver function, transplant eligibility, technical feasibility, and patient-specific factors [,]. Its role becomes particularly relevant when surgery is unsuitable because of limited hepatic reserve or when transplantation is not feasible, allowing curative-intent treatment of selected small tumors [,]. Radiofrequency ablation (RFA) has long served as the reference thermal technique. Alternating electrical current produces ionic agitation and tissue heating around the electrode, but the resulting ablation zone depends partly on conductive heat transfer. Blood flow in nearby vessels can remove heat from the target, creating the heat-sink effect and reducing treatment efficacy in perivascular tumors [,]. Microwave ablation (MWA) creates an electromagnetic field that produces rapid volumetric heating through molecular rotation and ionic polarization. In theory, this mechanism permits higher intratumoral temperatures, larger treatment zones, shorter application times, and less susceptibility to vascular heat loss than RFA [,]. Contemporary consensus recommendations nevertheless regard both modalities as acceptable first-line ablative treatments for early-stage HCC []. Earlier meta-analyses of randomized evidence generally reported comparable complete response and survival between the modalities, although some suggested improved disease control with MWA [,]. The overall evidence remains difficult to interpret because studies differ substantially in technology, procedural technique, tumor characteristics, follow-up, and endpoint definitions, with observational designs accounting for a large proportion of the available comparisons. We therefore performed an updated systematic review and meta-analysis of direct MWA-RFA comparisons in adults with HCC. The review evaluated initial complete ablation, local and distant recurrence, survival, complications, and periprocedural mortality; applied design-specific risk-of-bias tools; and rated outcome-level certainty using the Grading of Recommendations Assessment, Development and Evaluation (GRADE) framework. Review Methods Protocol and Registration Reporting was guided by the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) 2020 recommendations []. Before completion of the review, the protocol was registered with the International Prospective Register of Systematic Reviews (PROSPERO; CRD420261295141), where the research question, eligibility criteria, outcomes, and planned evidence-synthesis methods were prespecified. Analyses involving perivascular or subcapsular location, previous treatment status, baseline alpha-fetoprotein concentration, and liver disease etiology were subsequently added as exploratory post hoc analyses. Eligibility Criteria Study eligibility was structured around prespecified population, intervention, comparator, outcome, and study-design domains. We included adults aged 18 years or older with HCC diagnosed by clinical, imaging, or histopathologic criteria. Imaging-based diagnosis could follow the American Association for the Study of Liver Diseases, European Association for the Study of the Liver, or Liver Imaging Reporting and Data System criteria [,,]. Most participants had BCLC stage 0 or A disease, although selected stage B populations suitable for ablation were eligible. Inclusion required a head-to-head comparison of MWA and RFA within a randomized study or comparative observational cohort. Ablation performed percutaneously, laparoscopically, or through an open approach was eligible. Eligible designs comprised randomized controlled trials and nonrandomized comparative investigations, including prospective and retrospective cohorts, case-control designs, propensity score-matched cohorts, and analyses applying inverse probability of treatment weighting. Outcomes of interest were initial complete ablation, local tumor progression, intrahepatic distant recurrence, extrahepatic recurrence, overall survival, recurrence-free survival, major complications, minor complications, and periprocedural mortality. Noncomparative studies, preclinical or simulation studies, reports without separately extractable HCC results, duplicate or overlapping reports, systematic reviews, and previous meta-analyses were excluded. Publications had to be in English, Spanish, or Portuguese and dated 2005 or later. For recurrence and survival outcomes, at least 12 months of follow-up and 20 participants per treatment arm were required. The complete criteria are presented in Table . Information Sources and Search Strategy Searches were performed in PubMed/Medical Literature Analysis and Retrieval System Online (MEDLINE), Web of Science, Scopus, SciELO, and Latin American and Caribbean Health Sciences Literature (LILACS), covering each database from its inception to March 2026. Database-specific queries combined indexed terminology with free-text expressions describing HCC, MWA, and RFA. The electronic search was supplemented by citation searching of eligible reports and relevant reviews. Complete database-specific strategies are supplied in the supplementary material. Study Selection Once duplicate records had been removed, two investigators evaluated titles and abstracts independently. Publications considered potentially eligible were subsequently examined in full text by both reviewers using the predefined inclusion and exclusion criteria. Differences in eligibility judgments were first discussed between the reviewers and were referred to a third investigator when consensus could not be reached. The specific basis for exclusion was documented for each report removed at the full-text stage. The excluded full-text reports and their reasons are listed in Table [-]. During the final audit, the team identified incomplete acquisition of potentially eligible full texts. Supplementary retrieval recovered eight previously unavailable reports; six met the eligibility criteria and were added to the synthesis. The study database, risk-of-bias assessments, statistical analyses, tables, and figures were then regenerated. Data Extraction A long-format dataset was constructed with information recorded separately for each publication and treatment group. Extraction was performed in two stages. First, reported values were transcribed as presented in the source article together with their location in the document, without mathematical transformation. These data were then converted into standardized analytic formats, including event counts with denominators, proportions, means with standard deviations (SDs), and hazard ratios (HRs) with their confidence intervals (CIs) when available. Each reviewer independently completed the extraction process. When extracted values differed, the original publication was re-examined, and agreement was reached by discussion or, if necessary, consultation with a third reviewer. Numerical consistency was additionally checked by comparing reported percentages with the corresponding events and denominators. Extracted variables included publication characteristics, study design, recruitment period, diagnostic criteria, liver function, tumor number and size, anatomic location, baseline alpha-fetoprotein, primary or recurrent treatment status, treatment approach, device characteristics, follow-up, and efficacy and safety outcomes. The extraction domains are presented in Table . The prespecified outcomes and corresponding effect measures are presented in Table . Risk of Bias Assessment Randomized controlled trials were evaluated with the revised Cochrane Risk of Bias tool (RoB 2), whereas comparative nonrandomized studies were evaluated with the Risk of Bias in Non-randomized Studies of Interventions (ROBINS-I) tool [,]. Domain-level and overall judgments were assigned independently by two reviewers. For nonrandomized comparisons, particular attention was given to confounding by indication because allocation to MWA or RFA could have reflected tumor characteristics, technical accessibility, available technology, treatment era, or operator preference. Statistical Analysis Pooled effects were estimated under a random-effects framework. The between-study variance component was obtained using restricted maximum likelihood, while uncertainty around the pooled estimates incorporated the Hartung-Knapp-Sidik-Jonkman adjustment []. For dichotomous endpoints, treatment effects were expressed as Mantel-Haenszel risk ratios (RRs); time-to-event data were synthesized as hazard ratios using inverse-variance weighting. Heterogeneity across studies was characterized using I2 together with the estimated between-study variance, with prediction intervals reported when informative. Subgroup analyses were performed by study design. Meta-regression including 26 studies assessed mean tumor size as a study-level modifier of local tumor progression. Small-study effects were examined with contour-enhanced funnel plots and Egger regression when at least 10 studies contributed to an outcome []. Analyses were conducted in R using the meta and metafor packages (The R Core Team, R Foundation for Statistical Computing, Vienna, Austria) [,]. Certainty of Evidence Certainty was assessed separately for each outcome with the GRADE framework []. In accordance with GRADE methodology, randomized evidence entered the assessment at high certainty and nonrandomized evidence at low certainty. Outcome-specific ratings were subsequently downgraded when limitations related to bias, inconsistency, indirectness, imprecision, or publication bias were identified. Results Study Selection and Characteristics The electronic search yielded 4,496 records: 1,800 from PubMed/MEDLINE, 1,450 from Web of Science, 989 from Scopus, and 257 from SciELO and LILACS. Before screening, 1,071 duplicates and 1,102 records without an abstract were removed. The remaining 2,323 records underwent title-and-abstract review, and 2,261 were excluded. Sixty-two reports identified through database screening and one report identified through citation searching were sought for retrieval. Four reports could not be obtained, leaving 59 full-text reports for eligibility assessment. Twenty-one were excluded: 16 secondary, nonprimary, or preclinical reports; three reports without an eligible direct MWA-RFA comparison; one report without outcomes separable by treatment arm; and one duplicate or overlapping publication. Thirty-eight studies met the eligibility criteria. The complete selection process, database breakdown, and exclusion categories are shown in Figure . The 38 studies were published between 2005 and 2026 and contributed 8,347 participants in the analytic cohorts: 3,625 treated with MWA and 4,722 treated with RFA [-]. Seven reports were randomized controlled trials [-,,], and 31 were comparative nonrandomized studies. Most nonrandomized studies were retrospective cohorts; several used propensity score matching, and one used inverse probability of treatment weighting. The included studies and their risk-of-bias ratings are summarized in Table . Among randomized trials, one was rated at low overall risk of bias, five raised some concerns, and one was rated at high risk. Among nonrandomized studies, 17 were rated at moderate risk, 13 at serious risk, and one at critical risk. Confounding was the most frequent reason for serious or critical judgments. Initial Complete Ablation Twenty-eight studies involving 6,036 participants reported initial complete ablation. The pooled comparison showed no clinically meaningful difference between MWA and RFA (RR 1.01, 95% CI 1.00-1.02; I2=0%). Study-specific and pooled estimates are displayed in Figure . Local Tumor Progression Twenty-seven studies involving 5,166 participants reported local tumor progression. MWA was associated with a lower risk than RFA (RR 0.67, 95% CI 0.54-0.83; I2=54%). The association was present in both design strata: randomized controlled trials yielded RR 0.55 (95% CI 0.40-0.76; I2=0%), and comparative nonrandomized studies yielded RR 0.71 (95% CI 0.55-0.91; I2=59%). The design-stratified analysis is shown in Figure . Intrahepatic Distant Recurrence Fifteen studies involving 2,740 participants contributed to the analysis of intrahepatic distant recurrence. The pooled RR was 0.89 (95% CI 0.79-1.00; I2=45%). Although the point estimate favored MWA, the result did not establish a conclusive between-technique difference. The forest plot is presented in Figure . Survival Outcomes Only three studies reported usable HRs for overall survival and three for recurrence-free survival. The pooled HR was 1.12 for overall survival (95% CI 0.32-3.88; I2=66%) and 0.87 for recurrence-free survival (95% CI 0.38-1.99; I2=57%). Both estimates were imprecise because few studies provided comparable time-to-event data. Major and Minor Complications Twenty-six studies involving 5,493 participants contributed events to the meta-analysis of major complications. The pooled estimate did not demonstrate a conclusive difference (RR 1.12, 95% CI 0.87-1.45; I2=17%). Studies with zero events in both groups are displayed for completeness but do not contribute to the pooled ratio. The study-level results are shown in Figure . Fifteen studies involving 3,320 participants reported minor complications. The pooled RR was 1.16 (95% CI 0.96-1.38; I2=54%), without a conclusive difference between techniques. The corresponding forest plot is shown in Figure . Periprocedural Mortality Periprocedural death was uncommon. Four studies contributed events to the pooled analysis, producing an RR of 1.47 (95% CI 0.25-8.76; I2=0%). The wide interval reflects the small number of events and prevents a precise comparative safety estimate. Meta-Regression, Small-Study Effects, and Certainty Meta-regression did not identify mean tumor size as a statistically significant modifier of the local tumor progression effect (coefficient 0.12; P=.519). The fitted association and confidence band are presented in Figure . Contour-enhanced funnel plots showed no marked visual asymmetry. Egger regression was nonsignificant for the five outcomes with at least 10 contributing studies. The funnel plot for local tumor progression is presented in Figure . The certainty assessment was low for local tumor progression and very low for all remaining outcomes. The pooled estimates, absolute effects, heterogeneity, certainty ratings, and clinical interpretations are summarized in Table . Discussion The overall pattern observed in our analysis agrees with earlier quantitative reviews of MWA and RFA. Those studies generally found little difference in complete ablation or survival, while some identified a signal favoring MWA for control of the treated site [,,,]. Differences among previous estimates likely reflect variation in study selection, inclusion of observational evidence, ablation technology, tumor characteristics, and statistical methodology. The present analysis extends this literature by incorporating more recent comparative studies, evaluating randomized and nonrandomized evidence separately, and assessing outcome-level certainty using the GRADE framework. This synthesis of 38 studies and 8,347 participants found that MWA and RFA produced nearly identical initial complete ablation rates, whereas MWA was associated with less local tumor progression. The local-control association remained evident when randomized controlled trials were analyzed separately. In contrast, the available evidence did not show clear differences in intrahepatic distant recurrence, survival, complications, or periprocedural mortality. Immediate technical success and durability of tumor control should be interpreted as distinct clinical endpoints. Both technologies can eradicate the visible tumor in appropriately selected patients, which helps explain the RR of 1.01 for initial complete ablation. Later progression at the treated site may depend on whether a sufficiently wide and continuous ablation margin was created. MWA reaches high temperatures rapidly and is less dependent on conductive heat transfer, properties that may reduce distortion of the treatment zone near flowing vessels [-]. Comparative studies focused on perivascular HCC likewise suggest that this physical advantage can improve local control [,]. The magnitude of the observed MWA effect varied across the evidence base. Differences among studies in generator settings, applicator technology, number of antennas or electrodes, energy-delivery time, image guidance, operator practice, and definitions of local progression may partly account for the moderate heterogeneity. Margin assessment was also inconsistent. A tumor can meet imaging criteria for complete response even when the peripheral safety margin is inadequate, and insufficient margins are known to increase later local failure []. No conclusive reduction in intrahepatic distant recurrence was observed. This finding is biologically plausible because new tumors elsewhere in the liver are strongly influenced by cirrhosis, ongoing hepatic injury, microscopic multifocal disease, and de novo carcinogenesis rather than by the energy source used for the index lesion [,,,,]. Improved control of the treated site should therefore not be expected to eliminate distant intrahepatic recurrence. The survival analyses were underpowered. Only three studies supplied usable HRs for overall survival and three for recurrence-free survival, and the pooled intervals were wide. Survival in HCC also depends on hepatic functional reserve, cirrhosis decompensation, subsequent tumors, transplantation eligibility, salvage treatment, and comorbid disease [,,,,,]. The absence of a statistically conclusive survival difference should not be interpreted as proof of equivalence. Major and minor complication rates were also similar. Procedural safety depends heavily on the relationship of the tumor to the bile ducts, bowel, diaphragm, gallbladder, heart, and major vessels. Although MWA can create larger zones over shorter periods, that feature requires careful planning in complex locations. Hydrodissection, artificial ascites, and other displacement techniques may reduce injury to adjacent structures. The choice of energy source should therefore be integrated with anatomy, expected ablation geometry, imaging guidance, operator expertise, and available protective techniques [,]. This individualized approach is consistent with the BCLC, Complexity, Uncertainty, Subjectivity, Emotion (CUSE) framework, which emphasizes evidence-based treatment selection while incorporating clinical complexity, technical feasibility, oncologic risk, local expertise and resources, and patient-specific factors []. Methodological safeguards of this review included prospective protocol registration, independent duplicate screening and extraction, risk-of-bias tools selected according to study design, Hartung-Knapp-Sidik-Jonkman-adjusted random-effects synthesis, analyses stratified by design, and outcome-specific GRADE evaluation. These strengths should nevertheless be considered alongside several important limitations. Most evidence was nonrandomized and vulnerable to confounding by indication. The literature was concentrated in East Asia, where hepatitis B virus infection was common. Devices, procedural protocols, outcome definitions, and follow-up schedules varied. Reporting of ablation margins, perivascular location, technical parameters, and time-to-event outcomes was incomplete, limiting subgroup and survival analyses. An incomplete full-text acquisition process was identified during the final audit and corrected through documented supplementary retrieval. Finally, certainty was low for local tumor progression and very low for all other outcomes. Future randomized comparisons should adopt harmonized definitions for complete ablation, local tumor progression, and complications []. Detailed reporting of devices and procedural parameters, objective measurement of ablative margins, stratification according to tumor size and vascular proximity, and longer-term time-to-event follow-up would substantially improve comparability across trials. Patient-level data on procedure duration, treatment sessions, hospital stay, quality of life, additional treatments, and cost would help determine whether better local control translates into a meaningful advantage for particular patients. Conclusions In adults with HCC suitable for local ablation, MWA was associated with less local tumor progression than RFA, while initial complete ablation, safety, and survival outcomes were not demonstrably different. The most relevant distinction, therefore, appears to involve control of the treated site, potentially because MWA is less susceptible to the heat-sink effect. Both modalities remain valid first-line options. Selection should account for tumor location, the expected ablation margin, proximity to vulnerable structures, operator experience, procedural safety, device availability, and cost. More definitive comparisons will require randomized studies with sufficient statistical power, harmonized outcome definitions, and extended follow-up of time-to-event endpoints.